Trial Outcomes & Findings for Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (NCT NCT02681302)

Last Updated: 2025-07-25

Results Overview

To assess the safety of combined check point inhibition with nivolumab and ipilimumab after autologous hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence including patients with persistent and recurrent high risk diffuse large B cell lymphoma, high risk and recurrent T cell lymphoma and high risk and recurrent multiple myeloma. The composite endpoint consisting of the occurrence of at least one treatment-related limiting toxicity (after combined checkpoint inhibitor treatment is initiated) defined as a ≥ grade 4 non-hematologic toxicity as specified by the CTCAE. If 3 of 7 patients in a single group experience a treatment-related limiting toxicity, that single group will be terminated.

Recruitment status

TERMINATED

Study phase

PHASE1/PHASE2

Target enrollment

46 participants

Primary outcome timeframe

26 weeks

Results posted on

2025-07-25

Participant Flow

Participant milestones

Participant milestones
Measure	Group A De novo diffuse large B cell lymphoma that fails to achieve a PET negative complete response to primary rituximab and anthracycline based multi-agent chemotherapy and at least maintains stable disease after salvage chemotherapy or present double/triple hit features defined by overexpression by standard immunohistochemistry of c-MYC plus BCL2 and/or BCL6 or presence of chromosomal translocations as detected by break-apart FISH involving IGH/MYC plus IGH/BCL2 and/or IGH/BCL6 and who only received standard chemoimmunotherapy with rituximab, cyclophosphamide, vincristine and prednisone (R-CHOP) for induction and present at least stable disease after consolidation or salvage chemotherapy. Stable disease (SD) for lymphoma is defined in Appendix B: Lugano Classification for Response Assessment of Non-Hodgkin Lymphoma.	Group B Recurrent high-risk diffuse large B cell lymphoma defined as relapsing within one year of completion of rituximab and anthracycline based multi-agent chemotherapy or a sAAIPI (second-line age-adjusted International Prognostic Index) intermediate or high at relapse or acquisition of double/triple hit features upon relapse (as defined in group A) and at least stable disease after salvage chemotherapy. Patients with an initial diagnosis of low-grade/indolent non-Hodgkin lymphoma (i.e. follicular, marginal zone) who present relapse with histologic transformation to diffuse large B cell lymphoma (confirmed by biopsy) and meet the definition for high-risk as presented above, are also eligible.	Group C De novo high-risk T cell lymphoma with at least stable disease after primary therapy. High risk T cell lymphoma is defined as Stage III or IV disease at presentation and/or failure to achieve CR after frontline chemotherapy. Patients with ALK-positive ALCL will be excluded from the trial. Patients with ALK-negative ALCL in complete response will be excluded from the trial.	Group D Recurrent T cell lymphoma with at least stable disease after salvage therapy. Patients with ALK-positive ALCL will be excluded from the trial.	Group E Transplant-naïve high risk multiple myeloma with at least stable disease after most recent line of therapy. High risk myeloma is defined as those carrying 1q amplifications, 1p deletions, 13q deletions by conventional cytogenetics, p53 deletions, high-risk GEP 70 scores, t(4;14), t(14;16) and t(14;20), hypodiploidy. This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.	Group F Recurrent myeloma within 3 years after a single or tandem autologous transplant and at least stable disease after salvage therapy. Stable disease for multiple myeloma is defined in Appendix C: International Myeloma Working Group (IMWG). This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.
Overall Study STARTED	9	11	8	4	8	6
Overall Study COMPLETED	6	6	6	4	6	4
Overall Study NOT COMPLETED	3	5	2	0	2	2

Reasons for withdrawal

Reasons for withdrawal
Measure	Group A De novo diffuse large B cell lymphoma that fails to achieve a PET negative complete response to primary rituximab and anthracycline based multi-agent chemotherapy and at least maintains stable disease after salvage chemotherapy or present double/triple hit features defined by overexpression by standard immunohistochemistry of c-MYC plus BCL2 and/or BCL6 or presence of chromosomal translocations as detected by break-apart FISH involving IGH/MYC plus IGH/BCL2 and/or IGH/BCL6 and who only received standard chemoimmunotherapy with rituximab, cyclophosphamide, vincristine and prednisone (R-CHOP) for induction and present at least stable disease after consolidation or salvage chemotherapy. Stable disease (SD) for lymphoma is defined in Appendix B: Lugano Classification for Response Assessment of Non-Hodgkin Lymphoma.	Group B Recurrent high-risk diffuse large B cell lymphoma defined as relapsing within one year of completion of rituximab and anthracycline based multi-agent chemotherapy or a sAAIPI (second-line age-adjusted International Prognostic Index) intermediate or high at relapse or acquisition of double/triple hit features upon relapse (as defined in group A) and at least stable disease after salvage chemotherapy. Patients with an initial diagnosis of low-grade/indolent non-Hodgkin lymphoma (i.e. follicular, marginal zone) who present relapse with histologic transformation to diffuse large B cell lymphoma (confirmed by biopsy) and meet the definition for high-risk as presented above, are also eligible.	Group C De novo high-risk T cell lymphoma with at least stable disease after primary therapy. High risk T cell lymphoma is defined as Stage III or IV disease at presentation and/or failure to achieve CR after frontline chemotherapy. Patients with ALK-positive ALCL will be excluded from the trial. Patients with ALK-negative ALCL in complete response will be excluded from the trial.	Group E Transplant-naïve high risk multiple myeloma with at least stable disease after most recent line of therapy. High risk myeloma is defined as those carrying 1q amplifications, 1p deletions, 13q deletions by conventional cytogenetics, p53 deletions, high-risk GEP 70 scores, t(4;14), t(14;16) and t(14;20), hypodiploidy. This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.	Group F Recurrent myeloma within 3 years after a single or tandem autologous transplant and at least stable disease after salvage therapy. Stable disease for multiple myeloma is defined in Appendix C: International Myeloma Working Group (IMWG). This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.
Overall Study Withdrawal by Subject	1	1	0	1	0
Overall Study Screen Failure	2	4	2	1	1
Overall Study Discontinued Due to Updated FDA Risks	0	0	0	0	1

Baseline Characteristics

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Group A n=9 Participants De novo diffuse large B cell lymphoma that fails to achieve a PET negative complete response to primary rituximab and anthracycline based multi-agent chemotherapy and at least maintains stable disease after salvage chemotherapy or present double/triple hit features defined by overexpression by standard immunohistochemistry of c-MYC plus BCL2 and/or BCL6 or presence of chromosomal translocations as detected by break-apart FISH involving IGH/MYC plus IGH/BCL2 and/or IGH/BCL6 and who only received standard chemoimmunotherapy with rituximab, cyclophosphamide, vincristine and prednisone (R-CHOP) for induction and present at least stable disease after consolidation or salvage chemotherapy. Stable disease (SD) for lymphoma is defined in Appendix B: Lugano Classification for Response Assessment of Non-Hodgkin Lymphoma.	Group B n=11 Participants Recurrent high-risk diffuse large B cell lymphoma defined as relapsing within one year of completion of rituximab and anthracycline based multi-agent chemotherapy or a sAAIPI (second-line age-adjusted International Prognostic Index) intermediate or high at relapse or acquisition of double/triple hit features upon relapse (as defined in group A) and at least stable disease after salvage chemotherapy. Patients with an initial diagnosis of low-grade/indolent non-Hodgkin lymphoma (i.e. follicular, marginal zone) who present relapse with histologic transformation to diffuse large B cell lymphoma (confirmed by biopsy) and meet the definition for high-risk as presented above, are also eligible.	Group C n=8 Participants De novo high-risk T cell lymphoma with at least stable disease after primary therapy. High risk T cell lymphoma is defined as Stage III or IV disease at presentation and/or failure to achieve CR after frontline chemotherapy. Patients with ALK-positive ALCL will be excluded from the trial. Patients with ALK-negative ALCL in complete response will be excluded from the trial.	Group D n=4 Participants Recurrent T cell lymphoma with at least stable disease after salvage therapy. Patients with ALK-positive ALCL will be excluded from the trial.	Group E n=8 Participants Transplant-naïve high risk multiple myeloma with at least stable disease after most recent line of therapy. High risk myeloma is defined as those carrying 1q amplifications, 1p deletions, 13q deletions by conventional cytogenetics, p53 deletions, high-risk GEP 70 scores, t(4;14), t(14;16) and t(14;20), hypodiploidy. This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.	Group F n=6 Participants Recurrent myeloma within 3 years after a single or tandem autologous transplant and at least stable disease after salvage therapy. Stable disease for multiple myeloma is defined in Appendix C: International Myeloma Working Group (IMWG). This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.	Total n=46 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Age, Categorical Between 18 and 65 years	9 Participants n=5 Participants	5 Participants n=7 Participants	5 Participants n=5 Participants	3 Participants n=4 Participants	0 Participants n=21 Participants	5 Participants n=8 Participants	27 Participants n=8 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	6 Participants n=7 Participants	3 Participants n=5 Participants	1 Participants n=4 Participants	8 Participants n=21 Participants	1 Participants n=8 Participants	19 Participants n=8 Participants
Age, Continuous	51 Years n=5 Participants	66 Years n=7 Participants	57 Years n=5 Participants	52 Years n=4 Participants	69.5 Years n=21 Participants	50.5 Years n=8 Participants	62 Years n=8 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	1 Participants n=7 Participants	4 Participants n=5 Participants	1 Participants n=4 Participants	2 Participants n=21 Participants	2 Participants n=8 Participants	11 Participants n=8 Participants
Sex: Female, Male Male	8 Participants n=5 Participants	10 Participants n=7 Participants	4 Participants n=5 Participants	3 Participants n=4 Participants	6 Participants n=21 Participants	4 Participants n=8 Participants	35 Participants n=8 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Asian	0 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=8 Participants	5 Participants n=8 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Black or African American	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	3 Participants n=8 Participants	5 Participants n=8 Participants
Race (NIH/OMB) White	7 Participants n=5 Participants	11 Participants n=7 Participants	6 Participants n=5 Participants	2 Participants n=4 Participants	6 Participants n=21 Participants	2 Participants n=8 Participants	34 Participants n=8 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=8 Participants	0 Participants n=8 Participants
Race (NIH/OMB) Unknown or Not Reported	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=8 Participants	2 Participants n=8 Participants
Region of Enrollment United States	9 participants n=5 Participants	11 participants n=7 Participants	8 participants n=5 Participants	4 participants n=4 Participants	8 participants n=21 Participants	6 participants n=8 Participants	46 participants n=8 Participants

PRIMARY outcome

Timeframe: 26 weeks

Population: Patients at high risk for post-transplant recurrence including patients with persistent and recurrent high risk diffuse large B cell lymphoma, high risk and recurrent T cell lymphoma and high risk and recurrent multiple myeloma treated with nivolumab and ipilimumab after autologous hematopoietic stem cell transplantation

Outcome measures

Outcome measures
Measure	Group A n=7 Participants De novo diffuse large B cell lymphoma that fails to achieve a PET negative complete response to primary rituximab and anthracycline based multi-agent chemotherapy and at least maintains stable disease after salvage chemotherapy or present double/triple hit features defined by overexpression by standard immunohistochemistry of c-MYC plus BCL2 and/or BCL6 or presence of chromosomal translocations as detected by break-apart FISH involving IGH/MYC plus IGH/BCL2 and/or IGH/BCL6 and who only received standard chemoimmunotherapy with rituximab, cyclophosphamide, vincristine and prednisone (R-CHOP) for induction and present at least stable disease after consolidation or salvage chemotherapy. Stable disease (SD) for lymphoma is defined in Appendix B: Lugano Classification for Response Assessment of Non-Hodgkin Lymphoma.	Group B n=7 Participants Recurrent high-risk diffuse large B cell lymphoma defined as relapsing within one year of completion of rituximab and anthracycline based multi-agent chemotherapy or a sAAIPI (second-line age-adjusted International Prognostic Index) intermediate or high at relapse or acquisition of double/triple hit features upon relapse (as defined in group A) and at least stable disease after salvage chemotherapy. Patients with an initial diagnosis of low-grade/indolent non-Hodgkin lymphoma (i.e. follicular, marginal zone) who present relapse with histologic transformation to diffuse large B cell lymphoma (confirmed by biopsy) and meet the definition for high-risk as presented above, are also eligible.	Group C n=5 Participants De novo high-risk T cell lymphoma with at least stable disease after primary therapy. High risk T cell lymphoma is defined as Stage III or IV disease at presentation and/or failure to achieve CR after frontline chemotherapy. Patients with ALK-positive ALCL will be excluded from the trial. Patients with ALK-negative ALCL in complete response will be excluded from the trial.	Group D n=4 Participants Recurrent T cell lymphoma with at least stable disease after salvage therapy. Patients with ALK-positive ALCL will be excluded from the trial.	Group E n=7 Participants Transplant-naïve high risk multiple myeloma with at least stable disease after most recent line of therapy. High risk myeloma is defined as those carrying 1q amplifications, 1p deletions, 13q deletions by conventional cytogenetics, p53 deletions, high-risk GEP 70 scores, t(4;14), t(14;16) and t(14;20), hypodiploidy. This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.	Group F n=5 Participants Recurrent myeloma within 3 years after a single or tandem autologous transplant and at least stable disease after salvage therapy. Stable disease for multiple myeloma is defined in Appendix C: International Myeloma Working Group (IMWG). This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.
Safety of Combined Check Point Inhibition Therapy Via Assessment of Adverse Events and Lab Findings	2 Treatment-Related Limiting Toxicity	0 Treatment-Related Limiting Toxicity	0 Treatment-Related Limiting Toxicity	2 Treatment-Related Limiting Toxicity	1 Treatment-Related Limiting Toxicity	2 Treatment-Related Limiting Toxicity

Adverse Events

Group A

Serious events: 3 serious events

Other events: 7 other events

Deaths: 0 deaths

Group B

Serious events: 5 serious events

Other events: 7 other events

Deaths: 4 deaths

Group C

Serious events: 2 serious events

Other events: 5 other events

Deaths: 1 deaths

Group D

Serious events: 1 serious events

Other events: 4 other events

Deaths: 3 deaths

Group E

Serious events: 4 serious events

Other events: 7 other events

Deaths: 5 deaths

Group F

Serious events: 3 serious events

Other events: 5 other events

Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure	Group A n=7 participants at risk De novo diffuse large B cell lymphoma that fails to achieve a PET negative complete response to primary rituximab and anthracycline based multi-agent chemotherapy and at least maintains stable disease after salvage chemotherapy or present double/triple hit features defined by overexpression by standard immunohistochemistry of c-MYC plus BCL2 and/or BCL6 or presence of chromosomal translocations as detected by break-apart FISH involving IGH/MYC plus IGH/BCL2 and/or IGH/BCL6 and who only received standard chemoimmunotherapy with rituximab, cyclophosphamide, vincristine and prednisone (R-CHOP) for induction and present at least stable disease after consolidation or salvage chemotherapy. Stable disease (SD) for lymphoma is defined in Appendix B: Lugano Classification for Response Assessment of Non-Hodgkin Lymphoma.	Group B n=7 participants at risk Recurrent high-risk diffuse large B cell lymphoma defined as relapsing within one year of completion of rituximab and anthracycline based multi-agent chemotherapy or a sAAIPI (second-line age-adjusted International Prognostic Index) intermediate or high at relapse or acquisition of double/triple hit features upon relapse (as defined in group A) and at least stable disease after salvage chemotherapy. Patients with an initial diagnosis of low-grade/indolent non-Hodgkin lymphoma (i.e. follicular, marginal zone) who present relapse with histologic transformation to diffuse large B cell lymphoma (confirmed by biopsy) and meet the definition for high-risk as presented above, are also eligible.	Group C n=5 participants at risk De novo high-risk T cell lymphoma with at least stable disease after primary therapy. High risk T cell lymphoma is defined as Stage III or IV disease at presentation and/or failure to achieve CR after frontline chemotherapy. Patients with ALK-positive ALCL will be excluded from the trial. Patients with ALK-negative ALCL in complete response will be excluded from the trial.	Group D n=4 participants at risk Recurrent T cell lymphoma with at least stable disease after salvage therapy. Patients with ALK-positive ALCL will be excluded from the trial.	Group E n=7 participants at risk Transplant-naïve high risk multiple myeloma with at least stable disease after most recent line of therapy. High risk myeloma is defined as those carrying 1q amplifications, 1p deletions, 13q deletions by conventional cytogenetics, p53 deletions, high-risk GEP 70 scores, t(4;14), t(14;16) and t(14;20), hypodiploidy. This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.	Group F n=5 participants at risk Recurrent myeloma within 3 years after a single or tandem autologous transplant and at least stable disease after salvage therapy. Stable disease for multiple myeloma is defined in Appendix C: International Myeloma Working Group (IMWG). This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.
Gastrointestinal disorders Abdominal Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Adenoviremia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Endocrine disorders Adrenal Crisis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Alanine Aminotransferase Increased	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Alkaline Phosphatase Increased	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Aspartate Aminotransferase Increased	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Cardiac disorders Atrial Fibrillation	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Bilirubin Increased	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations C-Difficile	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations CPK Increased	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Dehydration	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Esophagitis	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Fever	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations GGT Increased	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Cardiac disorders Heart Block	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Hypotension	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Infection ESBL	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders L Leg Weakness	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Parainfluenza	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Pneumonia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Progression Of Disease	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Pseudomonas Aeruginosa Sepsis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Rigors	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations RSV Bronchiolitis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Sepsis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Sepsis - Pseudomona Bacteremia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Septic Shock	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Cardiac disorders STEMI	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Cardiac disorders STEMI, Heart Failure	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Syncope	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)

Other adverse events

Other adverse events
Measure	Group A n=7 participants at risk De novo diffuse large B cell lymphoma that fails to achieve a PET negative complete response to primary rituximab and anthracycline based multi-agent chemotherapy and at least maintains stable disease after salvage chemotherapy or present double/triple hit features defined by overexpression by standard immunohistochemistry of c-MYC plus BCL2 and/or BCL6 or presence of chromosomal translocations as detected by break-apart FISH involving IGH/MYC plus IGH/BCL2 and/or IGH/BCL6 and who only received standard chemoimmunotherapy with rituximab, cyclophosphamide, vincristine and prednisone (R-CHOP) for induction and present at least stable disease after consolidation or salvage chemotherapy. Stable disease (SD) for lymphoma is defined in Appendix B: Lugano Classification for Response Assessment of Non-Hodgkin Lymphoma.	Group B n=7 participants at risk Recurrent high-risk diffuse large B cell lymphoma defined as relapsing within one year of completion of rituximab and anthracycline based multi-agent chemotherapy or a sAAIPI (second-line age-adjusted International Prognostic Index) intermediate or high at relapse or acquisition of double/triple hit features upon relapse (as defined in group A) and at least stable disease after salvage chemotherapy. Patients with an initial diagnosis of low-grade/indolent non-Hodgkin lymphoma (i.e. follicular, marginal zone) who present relapse with histologic transformation to diffuse large B cell lymphoma (confirmed by biopsy) and meet the definition for high-risk as presented above, are also eligible.	Group C n=5 participants at risk De novo high-risk T cell lymphoma with at least stable disease after primary therapy. High risk T cell lymphoma is defined as Stage III or IV disease at presentation and/or failure to achieve CR after frontline chemotherapy. Patients with ALK-positive ALCL will be excluded from the trial. Patients with ALK-negative ALCL in complete response will be excluded from the trial.	Group D n=4 participants at risk Recurrent T cell lymphoma with at least stable disease after salvage therapy. Patients with ALK-positive ALCL will be excluded from the trial.	Group E n=7 participants at risk Transplant-naïve high risk multiple myeloma with at least stable disease after most recent line of therapy. High risk myeloma is defined as those carrying 1q amplifications, 1p deletions, 13q deletions by conventional cytogenetics, p53 deletions, high-risk GEP 70 scores, t(4;14), t(14;16) and t(14;20), hypodiploidy. This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.	Group F n=5 participants at risk Recurrent myeloma within 3 years after a single or tandem autologous transplant and at least stable disease after salvage therapy. Stable disease for multiple myeloma is defined in Appendix C: International Myeloma Working Group (IMWG). This cohort has been discontinued due to updated risks provided by the FDA. These patients will be followed for safety and correlative studies only.
Skin and subcutaneous tissue disorders Generalised Pruritis (Neck, Face, Chest)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Generalized Muscle Weakness	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Generalized Weakness	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Pruritus Localised (Palm And Soles)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Generalised Pruritis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Pruritus Torso, Arms	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Abdominal Pain	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Abdominal Pain (Right Upper Quad)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Acute Kidney Failure	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Adenoviremia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Endocrine disorders Adrenal Insufficiency	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Alanine Aminotransferase Increased	71.4% 5/7 • Number of events 14 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	80.0% 4/5 • Number of events 8 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 8 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Alkaline Phosphatase Increased	57.1% 4/7 • Number of events 6 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 13 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Allergic Rhinitis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Altered Mental Status	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Amylase Increased	57.1% 4/7 • Number of events 16 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 9 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 6 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Blood and lymphatic system disorders Anemia	100.0% 7/7 • Number of events 18 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	85.7% 6/7 • Number of events 69 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	80.0% 4/5 • Number of events 10 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	75.0% 3/4 • Number of events 6 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	71.4% 5/7 • Number of events 31 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	80.0% 4/5 • Number of events 52 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Blood and lymphatic system disorders Anemia (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Anorexia	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	42.9% 3/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	42.9% 3/7 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Psychiatric disorders Anxiety	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Aspartate Aminotransferase Increased	71.4% 5/7 • Number of events 13 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 9 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Cardiac disorders Atrial Fibrillation	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders B/L Axillary Swelling	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Back Pain	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Benign Lung Tissue (Bronchoscopy Result)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Bilirubin Increased	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 9 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Blepharitis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Bloating	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Blurry Vision	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Blurry Vision (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Brachial Plexopathy	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Bump/ Mass L Occiput	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Injury, poisoning and procedural complications Burn Right Wrist	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Burning Of Back	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Burning/Itching Eyes	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Cataract	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations C-Difficile	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Chest Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Chest Tightness	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Chest Tightness (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Chest Wall Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Chills	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Chronic Cough	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Colitis	28.6% 2/7 • Number of events 7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Psychiatric disorders Confusion	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Pulmonary Nodules	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Constipation	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Constipation (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Coronavirus	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Endocrine disorders Cortisol Decreased	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Cough	57.1% 4/7 • Number of events 9 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	57.1% 4/7 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Cough (Intermittent)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Cough Sequelae Of RSV	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Cough, Dry	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations CPK Increased	14.3% 1/7 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Cramping Hands, Legs (Intermittent)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Cramps	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Creatinine Increased	42.9% 3/7 • Number of events 7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 8 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	42.9% 3/7 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Dehydration	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Diarrhea	100.0% 7/7 • Number of events 17 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	71.4% 5/7 • Number of events 13 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	60.0% 3/5 • Number of events 11 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	57.1% 4/7 • Number of events 16 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 8 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Diarrhea (Intermittent)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Disease Progression	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Diverticulitis	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Dizziness	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Dizziness (Intermittent)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Drug Reaction	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Dry Mouth	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Dry Skin	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Dry Skin (Bl Le)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Dysgeusia	42.9% 3/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	60.0% 3/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Dyspepsia	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Dyspepsia (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Dyspnea	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Dyspnea (Intermittent)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Dyspnea On Exertion	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations E.Coli In Stool	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Early Satiety	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations EBV Reactivation	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Eczematous Dermatitis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Edema	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Edema (Limbs)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Edema BLE	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Edema LE	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Edema LLE	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Elevated Uric Acid	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Engraftment Syndrome	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Enterobactercloacae In Urine	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Enterovirus/Rhinovirus	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Eosinophilia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Epigastric Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Epistaxis	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Esophagitis	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Eye Burning	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Eye Burning (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Eye Irritation L	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Eye Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Eyelid Lesion	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Facial Edema	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Injury, poisoning and procedural complications Fall	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Fatigue	71.4% 5/7 • Number of events 9 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	42.9% 3/7 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	60.0% 3/5 • Number of events 13 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	57.1% 4/7 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 6 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Fecal Urgency	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Fever	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	60.0% 3/5 • Number of events 13 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Fever (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Fever/Chills	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Fevers (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Flank Pain (Right Side)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Flatulence	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Flu Like Symptoms	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Follicular Erythema Rash	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Gastritis	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations GGT Increased	71.4% 5/7 • Number of events 10 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	80.0% 4/5 • Number of events 7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	60.0% 3/5 • Number of events 13 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Graft Failure/Loss	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Haptoglobin Decreased	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Headache	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Headache (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Ear and labyrinth disorders Hearing Impaired	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Cardiac disorders Heart Failure, Systolic	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Heartburn	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Hematuria	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Hematuria/Dysuria/Fever	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Hemorrhoids	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Hiccups	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Hot Flashes	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Human Enterovirus/Rhinovirus	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Human Metapneumovirus	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypercalcemia	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hyperglycemia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hyperglycemia Non-Fasting	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 8 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hyperglycemia Non-Fasting (Intermittent)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 6 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hyperkalemia	14.3% 1/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	57.1% 4/7 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypermagnesemia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypernatremia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hyperphospatemia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Hypertension	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Endocrine disorders Hyperthyroidism	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hyperuricemia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Endocrine disorders Hypoadrenal	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypoalbuminemia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypocalcemia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Endocrine disorders Hypocortosolism	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Hypogammaglobulinemia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypoglycemia	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypoglycemia (Intermittent)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypokalemia	28.6% 2/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	57.1% 4/7 • Number of events 15 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypomagnesemia	28.6% 2/7 • Number of events 6 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 20 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypomagnesemia (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hyponatremia	28.6% 2/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 8 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Hypophosphatemia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 8 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Hypotension	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Hypotension (Orthostatic)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Endocrine disorders Hypothyroidism	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations IGG Decreased	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Immune System Disorder-Hypogammaglobulinemia	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Infection (+ Blood Culture)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Infection Adenovirus Reactivation	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Infection RSV	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Infection Sinus	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Influenza A	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Infusion Reaction (Sob, Feeling Cold, Rigors)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Infusion Related (Macupapular Rash)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Psychiatric disorders Insomnia	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Intermittent Vomiting	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Eye disorders Itchy Eyes (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Joint Pain (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Joint Range Of Motion Decreased (R Shoulder Rotator Cuff)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Joint Range Of Motion Decreased(Shoulder And Knees)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations LD Increased	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Left Arm Tingling	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Left Jugular Deep Vein Thrombosis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Leg Cramps (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Lethargy	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Leukocytosis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Leukopenia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Lip Infection	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Lipase Increased	28.6% 2/7 • Number of events 10 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 9 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Localized Edema	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Localized Edema (Left Arm)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Loose Stools (Pudding)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Lung Infection (Fungal Species: Mycelia Sterilia)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Lung Infection (Pna / Boop)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Lung Infection (Pna)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Lung Nodule	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Malaise	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Metapneumovirus And Coronavirus	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Mrsa Nasal Colonization	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Mucositis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Mucousy Stool (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Muscle Aches	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Muscle Weakness	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Muscle Weakness Lower Limb	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Myalgia (Left Leg)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Myalgia Bilateral Lower Extremities	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Myalgias	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Myopathy (Muscle Weakness Lower Limb)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Myositis /Polymyalgia Secondary To Late Effects Of Ipilimumab	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Nasal Congestion	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Nausea	28.6% 2/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	71.4% 5/7 • Number of events 10 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	57.1% 4/7 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Nausea (Dry Heaves)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Nausea (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Neuralgia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Neuropathic Leg Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Neutropenia	71.4% 5/7 • Number of events 34 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	85.7% 6/7 • Number of events 46 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	100.0% 5/5 • Number of events 23 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	50.0% 2/4 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	57.1% 4/7 • Number of events 18 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	100.0% 5/5 • Number of events 23 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Neutropenia (Intermittent)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Neutrophil Count Increased	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Nocturia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Nodule Occipital	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Norovirus	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Oral Candidiasis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Oral Mucositis	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Orthostatic Hypotension	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Orthostatic Hypotension (Adrenal Dysfunction)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Otitis Media (Right)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
General disorders Pain	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Pain Calf	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Pain Joint	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Pain Rib	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Pain Right Jaw	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Pain Right Lower Quadrant	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Pain To L Flank/Rib	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Pain-Bl Leg Pain Chronic Back Compressed Spinal Fracture	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Pancreatitis	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Papular Rash	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Parainfluenza A	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Parainfluenza	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Parainfluenza 1	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Parainfluenza 3 Lung Infection	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Paresthesia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Paresthesia Hands	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Pelvis Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Reproductive system and breast disorders Penile Lesion	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Peripheral Sensory Neuropathy	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Peripheral Sensory Neuropathy (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Perirectal Abscess	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Phosphorous Increased	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Pneumonia	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Postural Hypotension	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Pressure Ulcer	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Pruritus	14.3% 1/7 • Number of events 6 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	60.0% 3/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	42.9% 3/7 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Pruritus (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	42.9% 3/7 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash (Acneiform/Erythematous)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash (Around L Nipple)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash (Contact Dermatitis)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash (Erythematous)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash (Pruritic) Thighs	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash (Pruritic) Upper Chest	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash (R Hip)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash (Right Hand)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash Acneiform/Erythematous	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash Erythematous (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash Facial	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash Hands, Back	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash Maculopapular	28.6% 2/7 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 6 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash Pruritic	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash Pruritic (General)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rash, Acneiform/Erythematous	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rashes (Macular)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rashes (Papular Lower Lid)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rashes Acneiform	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rashes Forehead	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rashes Papular	28.6% 2/7 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Rashes Papular Chin	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Recurrent Clostridium Difficile Diarrhea	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Reflux	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Rhinitis	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Rhinovirus/Enterovirus (Rpp Virus)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Right Hip Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Right Upper Lobe Nodular Opacity	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Vascular disorders Rising Blood Pressure	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Shingles	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Short Term Memory Loss	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Cardiac disorders Sinus Tachycardia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Sinusitis	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Injury, poisoning and procedural complications Skin Biopsy Right Ear	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Skin Pigmentation	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Skin Tissue Pustules(Folliculitis)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Somnolence	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Respiratory, thoracic and mediastinal disorders Sore Throat	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Metabolism and nutrition disorders Steroid Induced Hyperglycemia (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Musculoskeletal and connective tissue disorders Stiff Neck	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Stomach Discomfort/Reflux	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Stomach Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Syncope	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Tachycardia	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Thrombocytopenia	85.7% 6/7 • Number of events 23 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	85.7% 6/7 • Number of events 32 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	60.0% 3/5 • Number of events 7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	75.0% 3/4 • Number of events 4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	42.9% 3/7 • Number of events 21 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	60.0% 3/5 • Number of events 40 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Thrush	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Tingling Painful Hands	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Tremors	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Nervous system disorders Tremors (Hand)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Endocrine disorders TSH Increased	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Upper Respiratory Infection	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Urinary Burning	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Urinary Disorder Straining	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Urinary Disorder Unable To Urinate	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Urinary Frequency	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Urinary Tract Infection	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Urinary Tract Infection (Enterobactercloacae Complex)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Renal and urinary disorders Urinary Tract Pain	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Uriticaria	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Vaginal Infection	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	25.0% 1/4 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Ear and labyrinth disorders Vertigo	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Infections and infestations Viral/Superimposed Bacterial Pneumonia	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Vomiting	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	57.1% 4/7 • Number of events 5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 3 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Gastrointestinal disorders Vomiting (Intermittent)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	20.0% 1/5 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations WBC Increased	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Investigations Weight Loss	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	28.6% 2/7 • Number of events 18 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	40.0% 2/5 • Number of events 2 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)
Skin and subcutaneous tissue disorders Wound, Sacral	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	14.3% 1/7 • Number of events 1 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/4 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/7 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)	0.00% 0/5 • From Day 1 Week 1 of combined checkpoint therapy through the end of the safety-reporting period of 100 days after the last dose of study therapy (approximately 40 weeks)

Additional Information

Joshua Zenreich

Hackensack Meridian Health

Phone: 551-996-4248

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place